Reply  by Olshansky, Brian et al.
In conclusion, we do believe that the report by Olshansky et al.
(1) from the AFFIRM study does not allow the conclusion that
“beta-blockers were the most effective drugs” in controlling ven-
tricular rate during atrial fibrillation. In their study, the efficacy of
beta-blockers and digoxin, both used alone, was equivalent. Our
opinion, in accordance with current guidelines for the management
of atrial fibrillation, is that digoxin is still a first-line alternative to
control ventricular rate in patients with atrial fibrillation, particu-
larly in cases with congestive heart failure and left ventricular
systolic dysfunction (4).
*Henrique H. Veloso, MD
Angelo A. V. de Paola, MD
*VOTCOR
Hospital da Venerável Ordem Terceira da Penitência
Rua Conde de Bonfim 1033
Rio de Janeiro
Brazil
E-mail: hhorta@cardiol.br
doi:10.1016/j.jacc.2005.03.015
REFERENCES
1. Olshansky B, Rosenfeld LE, Warner AL, et al., and the AFFIRM
Investigators. The Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) study: approaches to control rate in
atrial fibrillation. J Am Coll Cardiol 2004;43:1201–8.
2. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular
rate control in chronic atrial fibrillation during daily activity and
programmed exercise: a crossover open-label study of five drug regi-
mens. J Am Coll Cardiol 1999;33:304–10.
3. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG.
Carvedilol alone or in combination with digoxin for the management of
atrial fibrillation in patients with heart failure? J Am Coll Cardiol
2003;42:1944–51.
4. Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines
for the management of patients with atrial fibrillation: executive
summary. A report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines and the European
Society of Cardiology Committee for Practice Guidelines and Policy
Conferences (Committee to Develop Guidelines for the Management
of Patients with Atrial Fibrillation): developed in collaboration with the
North American Society of Pacing and Electrophysiology. J Am Coll
Cardiol 2001;38:1231–66.
5. Koh KK, Kwon KS, Park HB, et al. Efficacy and safety of digoxin alone
and in combination with low-dose diltiazem or betaxolol to control
ventricular rate in chronic atrial fibrillation. Am J Cardiol 1995;75:88–
90.
6. Ang EL, Chan WL, Cleland JG, et al. Placebo controlled trial of
xamoterol versus digoxin in chronic atrial fibrillation. Br Heart J
1990;64:256–60.
REPLY
We appreciate the interest of Drs. Veloso and de Paola and their
comments about our study (1).
We did not specifically recommend beta-blockers as the first-
line approach to rate control of atrial fibrillation in all patients.
Other therapeutic options, such as digoxin, may indeed be a more
appropriate first step in individual circumstances.
In the Atrial Fibrillation Follow-up Investigation of Rhythm
Management (AFFIRM) trial, more patients were switched to
beta-blockers than to other drug classes. Often, combination
therapy was needed. The question “is there one best approach?
cannot be answered definitively from our data for several reasons:
1. Rate control can be difficult. Drugs had to be changed in about
one-third of patients in the AFFIRM study. Effective rate
control may require open-mindedness to all rate-control op-
tions; there may be no one best approach for all patients.
2. Our study did not randomize the rate-control strategies. Some
patients required a beta-blocker or digoxin for other clinical
reasons. Beta-blockers may be necessary if the patient has
certain conditions, such as coronary artery disease, whereas
digoxin may be a first-line alternative when congestive heart
failure and left ventricular systolic dysfunction are present.
3. Rate control is difficult to define. The need for a specific rate
may vary by patient, by disease, and by drug. It is possible that
AFFIRM’s approach to rate control was too stringent or was
not targeting the correct rate.
4. Rate control might not be the only important end point in
managing atrial fibrillation with rate-controlling drugs. These
drugs may increase or decrease symptoms despite proper rate
control, influence mortality, affect total costs, influence hospi-
talization rates, or influence the return to sinus rhythm. These
factors, not explored in our report, must be considered for any
patient requiring therapy for rate control, and drug classes may
differ in this regard.
5. We could not analyze the combination of beta-blockers and
digoxin because start and stop dates for drug use were not
recorded in the AFFIRM study. Although it was possible to
determine whether neither drug was used, it was not possible
to determine whether both drugs were used concurrently.
The success of achieving rate control in the AFFIRM study may
have hinged on the flexibility of the investigators to use more than
one drug class. Over the long run, more patients were switched to
beta-blockers than to the other drug classes. Beta-blockers tended
to be used more commonly over time, and fewer patients aban-
doned this drug class. Of importance, rate control was possible for
the majority of patients without the need for atrioventricular
junctional ablation and a pacemaker, and rate control appeared to
improve over time.
We do not necessarily advocate a beta-blocker as first-line
therapy for rate control for all patients. Digoxin may be reasonable
as first-line therapy in some patients, especially sedentary elderly
patients.
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Atherosclerosis of the Aorta: A Risk Factor,
Risk Marker, or an Innocent Bystander?
In a recent issue of the Journal, Meissner et al. (1) should be
congratulated for carrying out a community-based transesophageal
echocardiography (TEE) study of thoracic aortic plaque. However,
because they included patients with descending aortic plaque
(which is more prevalent than arch plaque), their negative conclu-
sions regarding stroke are flawed. It is simply not plausible to
consider plaque limited to the descending aorta as a cause of
cerebral embolization.
Earlier studies of aortic arch plaque have found a 12% (2), 12%
(3), and 13.7% (4) risk of cerebral embolization. This is 50%
higher than the 8% risk of stroke in the “high risk” Stroke
Prevention in Atrial Fibrillation (SPAF)-III study patients (5). In
fact, if these “high risk” Stroke Prevention in Atrial Fibrillation
(SPAF) study patients had no significant plaque in the aorta on
TEE, their risk fell to 1.2%.
Although the investigators recognize this problem in their
limitations section, we would like to re-emphasize that aortic arch
plaque is associated with a high risk of stroke.
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REPLY
We appreciate the thoughtful comments of Drs. Tunick and
Kronzon to our study (1), “Atherosclerosis of the Aorta: Risk
Factor, Risk Marker, or Innocent Bystander?”
Plaques in the proximal descending aorta may theoretically
embolize retrogradely, as previously suggested (2).
Although the correlation of plaques in the descending aorta
with embolic cerebral events seems counterintuitive, location of
aortic atherosclerosis has not been shown to correlate clearly with
site of embolism. In the Stroke Prevention in Atrial Fibrillation
(SPAF)-III study, precisely the same definitions were used as in
our study. Almost all plaques were in the descending aorta,
whereas all embolic events were cerebral, suggesting that plaques in
the descending aorta do in some way correlate with stroke, as
high-risk markers, or, invoking the possibility of retrograde em-
bolism to some extent, as a direct source of embolism (3).
Nonetheless, we did secondary analyses of stroke end points in
subjects with only ascending and arch plaques (Table 5 in the
Meissner et al. [1] study) and similar results were obtained as was
commented upon in the discussion section. In our study, after
adjustment for age and gender, the hazard due to plaque was no
different from the baseline hazard.
Moreover, the results for a cerebrovascular event, in particular,
were essentially the same whether or not the descending aorta was
included or excluded in the analysis (hazard nonsignificantly
increased about 80%, after adjusting for age and gender, for both
models; Table 5 in the Meissner et al. [1] study). Further, before
adjusting for age and gender, the estimates of the increase in the
hazard of a cerebrovascular event were nearly the same both with
and without the descending aortic plaques included.
Finally, the studies referenced by Dr. Tunick and colleagues
were limited to patients with stroke who survived long enough to
be enrolled (4), to those referred for transesophageal echocardiog-
raphy (TEE) because of a specific indication (5), and to patients
with atrial fibrillation (3), whereas ours were randomly selected
community subjects without any indication for TEE. Our popu-
lation would be more representative of patients seen in the
community; consequently, they may not show the strong causal
association between aortic arch plaque as reported in studies of
highly selected (high-risk) patients.
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